Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01079741 |
Recruitment Status :
Completed
First Posted : March 3, 2010
Results First Posted : February 13, 2018
Last Update Posted : February 13, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma | Biological: NY-ESO-1 protein; Poly-ICLC; Montanide | Phase 1 Phase 2 |
This is a Phase I open label dose escalation study of the TLR3 agonist Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination in patients with high risk melanoma in clinical complete remission (cCr), followed by a randomized Phase II component in which patients will be randomized to subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide® ISA-51 VG (Montanide) (Arm B).
Patients with histological confirmed malignant melanoma, AJCC Stages: IIB, IIC, III or IV, who are in complete clinical remission (cCr) but at high risk of disease recurrence, will be eligible for enrollment, regardless of whether antigen expression in the autologous tumor can be demonstrated by either PCR or immunohistochemistry.
Primary Objectives:
- Phase I: To define the safety of subcutaneous vaccination with NY-ESO-1 protein, Montanide and escalating doses of Poly-ICLC.
- Phase II: To evaluate the induction of humoral and T cell (CD4+ and CD8+) immunity to subcutaneous vaccination with NY-ESO-1 protein in combination with Poly-ICLC when given with or without Montanide.
Exploratory analyses:
- Evaluation of primary tumor expression of NY-ESO-1 by IHC or RT-PCR.
- Histologic quantitation of original tumor TILs (tumor infiltrating lymphocytes), CD3+ cells, evaluation of mitotic index and correlation of this data with immunologic response.
- Correlation of NY-ESO-1 specific T cell responses with HLA type
- Investigation of polymorphisms for TLR3 through germline SNP analysis.
- Clinical Outcome (Time to Progression) reported descriptively.
- Skin section analysis of protein/adjuvant treated sites for immune cell infiltration and gene expression analysis
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 34 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ® ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission |
Study Start Date : | September 2010 |
Actual Primary Completion Date : | March 11, 2013 |
Actual Study Completion Date : | March 11, 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Dose-escalation component
Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
|
Biological: NY-ESO-1 protein; Poly-ICLC; Montanide
Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant. Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B). Other Names:
|
Active Comparator: Phase II is the randomized component.
The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
|
Biological: NY-ESO-1 protein; Poly-ICLC; Montanide
Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant. Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B). Other Names:
|
- Phase I, Number of Participants With SAE and DLT [ Time Frame: 52 weeks ]Safety measured by number of Serious Adverse Events per the CTEP v4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) and Dose Limiting Toxicity (DLT).
- CD4+ and CD8+ Response [ Time Frame: Up to 52 weeks ]Cellular response evaluated for the induction of cellular T cell (CD4+ and CD8+) immunity to subcutaneous vaccination with NY-ESO-1 protein in combination with Poly-ICLC when given with or without Montanide. Number of participants with increase CD4+ and CD8+ levels.
- NY-ESO-1 Expression by IHC [ Time Frame: up to 52 weeks ]Analysis of immune cell infiltration at the injection site by IHC. IHC analysis of immune cell infiltration was performed for each arm using a scoring system. 0: No expression of the marker of interest, 1: single cells or small clusters (<5 cells together) expressing marker of interest, 2: medium size clusters of cells expressing marker of interest, and 3: huge and homogeneously positive clusters of cells expressing marker of interest.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Histological diagnosis of malignant melanoma, stages IIB-IV in radiologically confirmed cCr without clinical evidence of disease.
- At least 4 weeks since surgery prior to first dosing of study agent.
-
Laboratory values within the following limits:
- Hemoglobin > 10.0 g/dL
- Neutrophil count > 1.5 x l09/L
- Lymphocyte count > Lower limit of institutional normal
- Platelet count > 80 x l09/L
- Serum creatinine < 2.0 mg/dL
- Serum bilirubin < 2 x upper limit of institutional normal
- AST/ALT < 2 x upper limit of institutional normal
- Patients must have an ECOG performance status of <2 (ECOG criteria published in [67].
- Life expectancy > 6 months.
- Age > 18 years.
- Able and willing to give written informed consent for participation in the trial (see Section 12.2).
Exclusion Criteria
- Serious illnesses, e.g., serious infections requiring antibiotics.
- Previous bone marrow or stem cell transplant.
- History of immunodeficiency disease (such as HIV) or autoimmune disease except vitiligo.
- Metastatic disease to the central nervous system.
- Other malignancy within 3 years prior to entry into the study, except for treated early-stage melanoma or non-melanoma skin cancer, or cervical carcinoma in situ.
- Prior chemotherapy or vaccine therapy.
- Radiation therapy, biological therapy or surgery within 4 weeks prior to first dose of study agent.
- Concomitant treatment with systemic corticosteroids greater than physiologic doses. Topical (but not at the proposed vaccination sites) or inhalational steroids are permitted.
- Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent.
- Pregnancy or lactation.
- Women of childbearing potential not using a medically acceptable means of contraception.
- Psychiatric or addictive disorders that may compromise the ability to give informed consent.
- Lack of availability of the patient for immunological and clinical follow-up assessment.
- Children <18 years of age who cannot undergo the leukapheresis procedure, do not meet the disease staging and/or the size criteria for frequent blood donations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01079741
United States, New York | |
New York University Langone Medical Center | |
New York, New York, United States, 10016 |
Principal Investigator: | Nina Bhardwaj, MD, PhD | NYU Langone Health | |
Principal Investigator: | Anna Pavlick, D.O. | NYU Langone Health |
Responsible Party: | Nina Bhardwaj, Director, Tumor Vaccine Program, Icahn School of Medicine at Mount Sinai |
ClinicalTrials.gov Identifier: | NCT01079741 |
Other Study ID Numbers: |
GCO 13-1391 |
First Posted: | March 3, 2010 Key Record Dates |
Results First Posted: | February 13, 2018 |
Last Update Posted: | February 13, 2018 |
Last Verified: | November 2017 |
Melanoma Skin Cancer Adjuvant Therapy Oncogenesis LAGE |
Cancer Immunity Neoplasms Immunogenicity Vaccine Immunotherapy |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Poly I-C Mineral Oil Carboxymethylcellulose Sodium Poly ICLC |
Freund's Adjuvant Interferon Inducers Immunologic Factors Physiological Effects of Drugs Laxatives Gastrointestinal Agents Antiviral Agents Anti-Infective Agents Adjuvants, Immunologic Emollients Dermatologic Agents |